ATTAIN

Main measures

• Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs

  up to 4 years

  Safety

• Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities

  up to 4 years

  Safety

• Number of Participants With Shifts From Baseline: Liver Function Laboratory Values

  Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

• Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry

  Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

• Number of Participants With Shifts From Baseline: Urinalysis

  Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

• The primary endpoints include the incidence of AEs, serious AEs (SAEs), and discontinuations of study treatment due to an AE, as well as the incidence of laboratory abnormalities.

  Safety

Relapsing MS · 18 to 65

As registered. Criteria can change, so ask the trial team or your neurologist.

In the sponsor's words

• Results

  Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.

  Mult Scler Relat Disord · 2022

• Results

  Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

  BMC Neurol · 2014

• Results

  Arnold DL, Shang S, Dong Q, Meergans M, Naylor ML. Peginterferon beta-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418795085. doi: 10.1177/1756286418795085. eCollection 2018.

• Results

  Seddighzadeh A, Hung S, Selmaj K, Cui Y, Liu S, Sperling B, Calabresi PA. Single-use autoinjector for peginterferon-beta1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study. Expert Opin Drug Deliv. 2014 Nov;11(11):1713-20. doi: 10.1517/17425247.2014.944159. Epub 2014 Jul 29.

• Referred to by

  POP

  Completed

• Extension of

  ADVANCE

  Phase 3 · Completed

Links found where a registry record names another trial's registry number.

• TWINS

  Phase 3 · Not yet recruiting

  Still running

• Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…

  Recruiting

  Still running

• Full Responders

  Phase 4 · Stopped early

  Stopped early

• A Study to Learn More About The Safety of Diroximel Fumar…

  Running, not recruiting

  Still running

• Study to Investigate Pregnancy Outcomes in Female Partici…

  Completed

  Result in a paper, not read yet

• 105MS306

  Phase 3 · Running, not recruiting

  Still running

1. Started

   Apr 2011

2. Main results due

   Oct 2015

3. Finished

   Oct 2015

4. Results posted

   Jan 2017